NASDAQ · Drug Manufacturers - Specialty & Generic · USD
Cardiol Therapeutics Inc. (CRDL) Stock Analysis
Cardiol Therapeutics Inc. (CRDL) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CRDL Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.15
- Previous Close
- $1.15
- Day's Range
- 1.15–1.19
- 52-Week Range
- 0.88–2.34
- Volume
- 617.28K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.73
Valuation
- Market Cap
- $142.17M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.25
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$33.82M
- Shares Outstanding
- 121.51M
- 1-Year Return
- −3.31%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 1.41M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CRDL closed at $1.17, −3.31% over 1 year.
Cardiol Therapeutics Inc. (CRDL) has a market capitalization of $142.17M.
In fiscal 2025, CRDL reported revenue of $0.00.
CRDL Stock Return by Calendar Year
Cardiol Therapeutics Inc. (CRDL) return since Jan 2019: what $10,000 became
- 1 year
- $10,000 $9,669
- −3.31%
- 5 years
- $10,000 $2,538
- −74.62%
- Since Jan 2019
- $10,000 $3,127
- −68.73%
If you had invested $10,000 in Cardiol Therapeutics Inc. (CRDL) at the close on January 15, 2019, the earliest close on record here, it would have been worth $3,127 at the close on October 21, 2026: −68.73% in total, −13.91% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +22.64% |
| 2025 | −25.47% |
| 2024 | +51.84% |
| 2023 | +65.29% |
| 2022 | −72.43% |
| 2021 | −15.14% |
| 2020 | −38.35% |
| 2019 | −5.51% |
As of October 21, 2026.
CRDL Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$33.82M | — |
| 2024 | $0.00 | −$36.68M | — |
| 2023 | $0.00 | −$28.13M | — |
| 2022 | $0.00 | −$30.93M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$34.32M | −$33.82M | — |
| 2024 | $0.00 | — | −$40.28M | −$36.68M | — |
| 2023 | $0.00 | — | −$29.79M | −$28.13M | — |
| 2022 | $0.00 | — | −$41.34M | −$30.93M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
BenzingaCardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
YahooCardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
BenzingaCardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
YahooCardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For Maveric
SeekingAlphaCardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
Yahoo
All 10 articles ↓Show fewer ↑
Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities
BenzingaCardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
YahooCardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
YahooCanaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$63.67B
TEVATeva Pharmaceutical Industries Limited
$47.37B
HLNHaleon plc
$44.06B
ZTSZoetis Inc.
$32.90B
UTHRUnited Therapeutics Corporation
$24.17B
VTRSViatris Inc.
$21.19B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B